| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
ORIGINAL ARTICLES |
From the Departments of Surgery (IB, JS, FRS, DLF, LSC, BJC) and Radiology (SGO, MS), University of Pennsylvania, Philadelphia; and the Department of Pathology (CR), Mayo Clinic, Rochester, Minnesota.
Correspondence: Address correspondence and reprint requests to: Brian J Czerniecki, MD, PhD, Department of Surgery, 4 Silverstein, HUP, 3400 Spruce St., Philadelphia, PA 19104; Fax: 215-662-7476; E-mail: czerniec{at}mail.med.upenn.edu
| ABSTRACT |
|---|
|
|
|---|
Methods: A retrospective review was performed of 231 patients with invasive breast cancer or ductal carcinoma-in-situ who had MRI as part of their evaluation and treatment at the University of Pennsylvania between 1992 and 1998. Clinical, radiological, and pathologic data were examined.
Results: MRI needle localization was performed in 41 (18%) patients. MRI needle localization was required for a finding of a mammographically or clinically occult lesion in 31 patients, better MRI definition of tumor in 5 patients, and surgeons choice in 5 patients. In all cases, MRI localization and excisional biopsy were successfully completed. Nineteen of 31 patients were found to have additional mammographically and clinically occult tumors. There were 12 (29%) false-positive MRI scans.
Conclusions: MRI has a high sensitivity for detection of breast cancer; additional mammographically and clinically occult sites of tumor are detected in approximately 1 (15%) of 7 breast cancer patients. These otherwise occult sites of disease can be appropriately biopsied with MRI needle-localization techniques.
Key Words: Magnetic resonance imaging Breast cancer Biopsy Mammography
| INTRODUCTION |
|---|
|
|
|---|
As a diagnostic modality in breast cancer patients, magnetic resonance imaging (MRI) of the breast has been shown to have high sensitivity (94%100%).79 In addition, in these highly selected patients, MRI demonstrates other unsuspected areas of cancer in approximately one third of such cohorts.8,9 Comparative studies of MRI to mammogram, ultrasound, and clinical assessment consistently show MRI to have higher accuracy for determining the extent of disease, including the presence of multifocal or multicentric disease.1012 However, the specificity of breast MRI remains highly variable (37%100%)7,8,13 and overall is lower than would be desired, because of the enhancement of some benign breast lesions with the administration of contrast.14,15 Therefore, the optimal management of lesions seen on MRI alone remains to be determined. We undertook this study to determine whether MRI needle localization was feasible for assessing the pathology of lesions observed on breast MRI.
| METHODS |
|---|
|
|
|---|
MRI and Needle-Localization Biopsy
Breast MRI was performed with a 1.5-tesla GE Signa HorizonTM echo speed system (Fairfield, CT) with a compression breast array. Before-and-after intravenous gadolinium MRI scans were performed by using 2-mm slices and 350 x 700-µm in-plane resolution. Findings of enhancement in a ductal or regional distribution were considered to be in situ carcinoma. Focal mass enhancement was considered to be representative of invasive cancer.
For needle localization, a lateral plate containing a window measuring approximately 6.25 x 3.75 cm was centered over the area suggestive of malignancy. The location of the lesion was identified on an MRI. The x, y, and z dial positions were calculated with software to accurately position the needle guide. Each of the three dial positioning dials could be moved in intervals of .025 mm. After the dials were appropriately set, the needle was passed into the area of interest. The wire position was subsequently verified for the surgeon by mammography (Fig. 1).
|
| RESULTS |
|---|
|
|
|---|
|
Results of Biopsy
All patients undergoing MRI needle-localization biopsy were successfully localized, and excisional biopsy was performed. Biopsy results for the 31 cases of MRI-localized lesions are diagrammed in Fig. 3. Of the 31 previously unsuspected sites suggestive of disease detected by MRI only, 19 (62%) were confirmed as malignant at biopsy. The sizes of these MRI-detected lesions ranged from 4 mm to several centimeters. The histology of these additional sites of disease was predominantly invasive; two patients had pure DCIS lesions picked up by MRI alone.
|
|
Change in Treatment on the Basis of Preoperative MRI
All 31 patients with unsuspected disease seen on preoperative MRI had biopsy of these areas suggestive of disease (Fig. 3). Among the 19 patients with additional tumor foci confirmed at biopsy, the preoperative plan was altered in 13, with 11 patients previously believed to be breast-conservation therapy candidates converted to mastectomy. In addition, two patients with axillary masses were able to undergo breast-conservation therapy rather than the planned modified radical mastectomy.
Twelve patients had a negative biopsy at sites of MRI-suspected tumor; eight of these patients had an additional biopsy through a separate incision. In the remaining four patients, a wider excision was performed to incorporate the area of MRI abnormality.
| DISCUSSION |
|---|
|
|
|---|
At the University of Pennsylvania, we have pursued attempts at biopsy of MRI abnormalities before definitive surgery. In this study, 31 patients were identified for MRI needle-localization biopsy. Because the current ability to core biopsy under MRI guidance remains limited, these patients underwent needle localization by MRI followed by excisional biopsy. Biopsy was successfully completed in all 31 patients. Nineteen of these patients had additional sites of malignancy identified by MRI. It is important to note that eight of these patients had multicentric disease that probably would have been missed if the patient had opted for treatment of the index lesion with breast conservation. Whether these MRI-detected, but mammographically and clinically occult, tumors can be appropriately treated with radiotherapy remains controversial. The addition of radiotherapy reduces the risk of ipsilateral tumor recurrence; however, long-term recurrence rates remain at approximately 10% to 20%.1618 It remains unclear whether such recurrences are due to inadequate excision of the primary tumor or to unsuspected multifocal or multicentric disease.3,16,19,20 Prospective studies using MRI for more accurate staging will be required to assess the long-term effect of the preoperative use of this new staging modality on ipsilateral breast tumor recurrence.
Our study identified MRI as a useful tool for further evaluation of a certain subpopulation of patientsspecifically, patients with inadequately visualized or indeterminate lesions on mammography or patients with atypical presentations. In all five patients in our study population with suspicious but poorly defined lesions on mammogram, the tumor was well localized for biopsy by MRI. In five of six patients with carcinoma presenting with an axillary mass or nipple discharge and a negative mammogram, MRI was able to localize the primary tumor. In a review from our institution of 22 patients presenting with axillary node metastasis and unknown primary malignancy, MRI successfully identified a primary breast cancer in 19 patients (86%).21 Similarly, the recently published experience from Memorial Sloan-Kettering Cancer Center further supports the use of MRI for localizing and thereby facilitating breast conservation in this patient population.22 Therefore, we believe that MRI should be considered in all patients presenting with axillary disease and with no primary tumor identified in the breast on clinical examination or mammography.
Although breast MRI seems to identify otherwise occult tumors and consequently to affect surgical management, caution needs to be exercised in using this modality. At present, the specificity of this imaging modality is lower than would be desired, and, as seen in our study, a significant number of patients undergo biopsy with benign findings. Although MRI as a single-step staging tool may be cost-effective,23 we believe that until the specificity of this tool is significantly and reliably improved, MRI findings should be confirmed by biopsy before definitive surgery. Needle-localization biopsy is clearly feasible; however, it is expensive and time consuming, and it adds a small but definite risk of morbidity. Development of core biopsy techniques that are MRI compatible will be important in advancing this area of patient care.
Additionally, although all patients to date have been successfully localized by MRI for biopsy, a number of technical difficulties have become obvious. First, unlike needle localization under mammography, the specimen removed after MRI localization cannot be imaged to confirm that the area suggestive of disease has in fact been removed. Although we did not in this study consistently reimage the patients with MRI after biopsy to verify that the suspicious lesion identified on MRI had in fact been removed, we have had many instances of interval postbiopsy MRI evaluations that confirm the success of the MRI-guided needle-localization biopsy. Second, all lesions in the breast localized by MRI are approached laterally, therefore making it somewhat more challenging for the surgeon to access and remove a medial lesion.
| CONCLUSIONS |
|---|
|
|
|---|
Received for publication September 10, 2001. Accepted for publication February 9, 2002.
| REFERENCES |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
D. Black, M. Specht, J. M. Lee, F. Dominguez, M. Gadd, K. Hughes, E. Rafferty, and B. Smith Detecting Occult Malignancy in Prophylactic Mastectomy: Preoperative MRI Versus Sentinel Lymph Node Biopsy Ann. Surg. Oncol., September 1, 2007; 14(9): 2477 - 2484. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Pruthi, K. R. Brandt, A. C. Degnim, M. P. Goetz, E. A. Perez, C. A. Reynolds, P. J. Schomberg, G. K. Dy, and J. N. Ingle A Multidisciplinary Approach to the Management of Breast Cancer, Part 1: Prevention and Diagnosis Mayo Clin. Proc., August 1, 2007; 82(8): 999 - 1012. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. D. Lehman, E. R. DePeri, S. Peacock, M. D. McDonough, W. B. DeMartini, and J. Shook Clinical Experience with MRI-Guided Vacuum-Assisted Breast Biopsy Am. J. Roentgenol., June 1, 2005; 184(6): 1782 - 1787. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. E. Deurloo, S. H. Muller, J. L. Peterse, A. P. E. Besnard, and K. G. A. Gilhuijs Clinically and Mammographically Occult Breast Lesions on MR Images: Potential Effect of Computerized Assessment on Clinical Reading Radiology, March 1, 2005; 234(3): 693 - 701. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Liberman, E. A. Morris, D. D. Dershaw, A. F. Abramson, and L. K. Tan MR Imaging of the Ipsilateral Breast in Women with Percutaneously Proven Breast Cancer Am. J. Roentgenol., April 1, 2003; 180(4): 901 - 910. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |